The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
 
Olivier Jules van Not
No Relationships to Disclose
 
Alfonsus Johannes Maria van den Eertwegh
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - BMS; Roche; Sanofi
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche; Sanofi
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Maureen J.B. Aarts
Research Funding - Pfizer (Inst)
 
Franchette van den Berkmortel
No Relationships to Disclose
 
Jan Willem de Groot
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; SERVIER
 
Geke Hospers
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; Seerave Foundation
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Pierre Fabre (Inst)
Research Funding - BMS (Inst)
Travel, Accommodations, Expenses - Roche
 
Djura Piersma
No Relationships to Disclose
 
Rozemarijn Van Rijn
No Relationships to Disclose
 
Marion Stevense
No Relationships to Disclose
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Gerard Vreugdenhil
No Relationships to Disclose
 
Marye Boers-Sonderen
Consulting or Advisory Role - MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
 
Han J. Bonenkamp
No Relationships to Disclose
 
Anne M.L. Jansen
No Relationships to Disclose
 
Willeke Blokx
No Relationships to Disclose
 
Michel W.J.M. Wouters
No Relationships to Disclose
 
Karijn Suijkerbuijk
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Speakers' Bureau - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD (Inst); Roche (Inst)